Advertisement
UK markets close in 6 hours 40 minutes

  • FTSE 100

    8,091.42
    +51.04 (+0.63%)
     

  • FTSE 250

    19,710.43
    -8.94 (-0.05%)
     

  • AIM

    754.95
    +0.26 (+0.03%)
     

  • GBP/EUR

    1.1672
    +0.0027 (+0.24%)
     

  • GBP/USD

    1.2523
    +0.0060 (+0.48%)
     

  • Bitcoin GBP

    50,932.35
    -2,277.37 (-4.28%)
     

  • CMC Crypto 200

    1,360.93
    -21.64 (-1.56%)
     

  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     

  • DOW

    38,460.92
    -42.77 (-0.11%)
     

  • CRUDE OIL

    83.15
    +0.34 (+0.41%)
     

  • GOLD FUTURES

    2,339.80
    +1.40 (+0.06%)
     

  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     

  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     

  • DAX

    17,994.78
    -93.92 (-0.52%)
     

  • CAC 40

    8,063.95
    -27.91 (-0.34%)
     
Property:

How to sell your home

Top tips from property investors

Is Geron (GERN) Outperforming Other Medical Stocks This Year?

Zacks Equity Research
·2-min read

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Geron (GERN) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? One simple way to answer this question is to take a look at the year-to-date performance of GERN and the rest of the Medical group's stocks.

Geron is a member of our Medical group, which includes 888 different companies and currently sits at #1 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. GERN is currently sporting a Zacks Rank of #2 (Buy).

The Zacks Consensus Estimate for GERN's full-year earnings has moved 27.83% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.

ADVERTISEMENT

According to our latest data, GERN has moved about 13.23% on a year-to-date basis. Meanwhile, the Medical sector has returned an average of -1.41% on a year-to-date basis. This means that Geron is performing better than its sector in terms of year-to-date returns.

Breaking things down more, GERN is a member of the Medical - Biomedical and Genetics industry, which includes 382 individual companies and currently sits at #19 in the Zacks Industry Rank. Stocks in this group have gained about 7.21% so far this year, so GERN is performing better this group in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to GERN as it looks to continue its solid performance.


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Geron Corporation (GERN) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research